company_description
stringlengths 13
1.56k
⌀ | company_website
stringlengths 7
88
⌀ | private_or_public
stringclasses 14
values | slogan
stringlengths 3
172
⌀ | location
stringlengths 5
74
⌀ | found_in_year
stringclasses 25
values | investors
stringlengths 0
153
⌀ | company_status
stringlengths 5
174
⌀ | company_products_or_services
stringlengths 67
1.03k
| problem_being_solved
stringlengths 0
663
⌀ | solution_offered
stringlengths 24
706
⌀ | value_proposition_x
stringlengths 39
950
⌀ | business_model
stringlengths 11
1.15k
⌀ | technology_used
stringlengths 68
941
⌀ | executive_summary
stringlengths 313
2.33k
⌀ | filename
stringlengths 89
159
| category
stringclasses 3
values | revenues
stringlengths 3
117
⌀ | market_cap
stringlengths 3
136
⌀ | stock_symbol_and_price
stringlengths 2
105
⌀ | funding_amount_or_round
stringlengths 3
281
⌀ | operating_margin
stringlengths 3
76
⌀ | pe_ratio_or_margin
stringlengths 3
151
⌀ | leadership
int64 -1
5
| capital_and_financial_mgmt
int64 -1
5
| differentiation
int64 -1
5
| business_model_and_channel
int64 -1
5
| marketing
int64 -1
5
| company_culture
int64 -1
5
| resilience_and_pivots
int64 -1
5
| fulfilling_customer_needs
int64 -1
5
| laws_regulations_ip
int64 -1
5
| value_proposition_y
int64 -1
5
| timing
int64 -1
5
| product_design_and_idea
int64 -1
5
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
They focus on Adverse Childhood Experiences (ACEs) and early-life adversity, tackling their profound effects on personal well-being and intergenerational trauma. From behavior and epigenetics to physical health, their approach addresses how trauma is transmitted across generations, helping to create lasting change for both individuals and families.They leverage responsible AI to enhance their systems, focusing on reducing harm and doing no harm. Their technology enables personalized interventions and predictive behaviors, driving improved health outcomes while ensuring ethical and safe practices. | https://www.cepanoa.com | Private | Cepanoa is dedicated to transforming lives through human-centered care and responsible AI - starting with profunda health | Redwood City, CA | 2023 | null | Growth | 1 paragraph to list the offerings, including products and services being sold. | Cepanoa health aims to help children handle trauma. | They provide affordable and accessible therapy solutions through technology to match patients with qualified advisors and doctors. | Cepanoa health provides a type of healthcare which has a holistic approach, which is not typically found in doctors offices or with therapists. | Advertising with personalized plans tailored to each patient. | Cepanoa leverages AI backed software in order to allow treatment to become more accessible for communities who have typically not received proper health coverage. | Cepanoa health succeeds in their mission to help children with trauma through increasing accessibility, something that has not been done before. Gomez, founder and CEO, holds this close to her heart as she is very connected to her company’s mission. Although they have not proceeded with any funding yet, they have successfully bootstrapped for the past few years. Cepanoa is early stage ore seed company, therefore there is not much to analyze about capital and financial management. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/corrylarissa_LATE_5614369_91339050_Spring2025_BusinessProfileFormat copy.docx | Healthcare Profile | null | null | null | Pre seed | null | null | 4 | 3 | 4 | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 5 | 4 |
Abridge AI Inc. is a healthcare technology company founded in 2018 and based in Pittsburgh, Pennsylvania. It uses artificial intelligence to help doctors and nurses with their paperwork by turning conversations with patients into organized clinical notes. This makes documentation easier, giving healthcare professionals more time to focus on patient care. | https://www.abridge.com/ | Private | We Transform Conversations Into Insights With AI | Pittsburgh, Pennsylvania, USA | 2018 | Elad Gil, IVP, Bessemer Venture Partners, Lightspeed Venture Partners, CVS Health Ventures, Redpoint Ventures, NVentures, among others | Hypergrowth | Abridge offers an AI-powered platform that records and transcribes medical conversations between clinicians and patients, generating structured clinical notes. These notes integrate seamlessly with electronic health record (EHR) systems, streamlining clinical workflows and allowing healthcare providers to focus more on patient care. | Healthcare professionals often face significant administrative burdens due to extensive documentation requirements, leading to burnout and reduced time for patient care | Abridge's AI-driven platform automates the transcription and structuring of clinical conversations, reducing the time clinicians spend on documentation. | Abridge’s AI-driven solutions streamline healthcare documentation, so healthcare teams can focus on what matters most: delivering the best care to people. | Abridge operates on a subscription-based model, partnering with healthcare systems and providers who pay for access to its AI documentation services. | The company's platform utilizes advanced machine learning and natural language processing techniques to accurately transcribe and summarize medical conversations. This technology ensures that the generated clinical notes are both comprehensive and compliant with medical documentation standards. | Abridge AI Inc., founded in 2018, is a healthcare technology company based in Pittsburgh, Pennsylvania. The company specializes in using artificial intelligence to streamline healthcare documentation by converting patient-clinician conversations into structured clinical notes. This innovation reduces the administrative burden on healthcare professionals, allowing them to spend more time on patient care. With strong leadership and a growing demand for AI solutions in healthcare, Abridge has positioned itself as a key player in the industry. Abridge's success is largely driven by its strong leadership (ranked 5) and excellent timing (ranked 5), which have enabled it to capitalize on the increasing need for AI-powered healthcare solutions. The company has secured substantial funding, providing a solid financial foundation for growth. However, Abridge faces challenges in resilience and pivots (ranked 2) and differentiation (ranked 3), as the rapidly evolving healthcare tech landscape requires constant innovation their product could be improved to be more comprehensive and flexible for different healthcare teams. Despite these challenges, Abridge's focus on reducing clinician workload and improving patient care positions it for continued success in the market. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/cortinadanica_LATE_5659051_91339399_Abridge AI.docx | Healthcare Profile | $50 million in 2024 | null | N/A not yet IPO | Total funding of $457.5 million over seven rounds, with the latest being a $250 million Series D on February 17, 2025 | Estimated to be approximately 10 Million | N/A | 5 | 4 | 3 | 3 | 4 | 5 | 2 | 4 | 3 | 4 | 5 | 4 |
PicnicHealth is a series C1 health technology startup aiming to simplify health record management for both patients and healthcare researchers. They built a platform where patients can access and manage all of their medical records in one place at the same time allowing them to participate in healthcare research. On the other hand, they accelerate healthcare research process for researchers by providing them quick and easy access to medical data directly from patients. | https://picnichealth.com/ | Private | Healthcare Simplified with the Universal Patient Record | San Francisco, CA | 2014 | B Capital Group, Felicis, Y Combinator | Growth to Hypergrowth | 1 paragraph to list the offerings, including products and services being sold. | To Patients: Managing health records is messy | Unified Medical Record, a digital platform to keep everything in one place | Easily mange all health records in one place
To Researchers: Gathering participants takes a long time | Provide Abundant Patient Data for Efficient Observational Research | Accelerate the observational research by quickly getting access to abundant data | Unified Medical Record, a digital platform to keep everything in one place | Easily manage all health records in one place | The patient side is free. Partner with life science companies and charge them based on the data they want access. | PicnicHealth built a data management platform, a mobile software application, and a LLM agent, Picnic AI trained on over 32 million patient records that enhance the user experience. | PicnicHealth built a platform that addresses pain points for both patients and life science researchers. They designed an easy and minimalist patient side user experience for managing all health records along with a LLM chat based agent that quickly answer questions regarding their health records for users. On the other hand, they collaborate closely with researchers and big healthtech companies by offering them a more efficient venue of getting access to health data for accelerating the healthcare research.
PicnicHealth has a strong leadership team and advisory board, along with beyond financial supports from major venture capital firms. Their unique product and business model will lead them into supergrowth soon as their flywheel is on the verge of spinning once they put some incentive into the patient side marketing. Then, they will have a network effect that serve as their greatest moat. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/daichen_LATE_5570840_91342609_Heath_BusinessProfileFormat.docx | Healthcare Profile | null | null | null | Series C1 | null | null | 5 | 5 | 5 | 5 | 3 | 4 | -1 | -1 | -1 | 5 | -1 | 5 |
Clarify Health’s purpose is to take patient data and use its AI and machine learning models to interpret it and to create better personalized patient healthcare plans. The purpose behind this is to improve patient outcomes and to use resources more efficiently so as to increase stockholder value. | https://clarifyhealth.com/ | Private | “Blueprinting a healthcare system that benefits all” | San Francisco | 2015 | 20 Investors $352.96 Million Raised | Growth | The company’s main product is its AI and machine learning models. With these, it is able to process patient and healthcare data to not only provide better plans for better patient outcome, but it is also able to give C-suite executives better data on the operations of a given region. In doing so, the executives are able to see where resources are being used efficiently and where efficiency is lacking. | Patient healthcare regimes are too standardized and require more personalization in order to improve outcomes and efficiency | AI and machine learning programs to analyze data and offer better information | Clarify’s value proposition is that it wants to provide better information regarding patients to allow for better use of healthcare resources and to improve patient outcomes. | Subscription model for hospitals and other healthcare providers. | The company utilizes AI, predictive analytics, machine learning, and real-time patient navigation in order to guide patients and caregivers through personalized healthcare plans. The company hopes that by using this technology, it can help healthcare providers to produce personalized plans for each of their patients, as opposed to standardized models, in order to have better outcomes for the patients. | Started in 2015 by Jean Drouin and Todd Gottula, Clarify Health began with the purpose of attempting to improve patient experiences and improving efficiency within the healthcare system. In order to do this, it has focused on AI-powered tools in order to analyze data and provide necessary information to patients, providers, and executives. The company’s timing has worked well to coincide with the rise of AI, allowing for a more mature product, and overall seems to be on track to becoming a larger play in the healthcare industry as it promises to offer increases in stockholder value. The company appears to be well received by the market with its current valuation of $1.5 billion. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/diazgilberto_LATE_5577542_91338641_Spring2025_BusinessProfileFormat_HealthcareAI.docx | Healthcare Profile | null | null | null | $352.96 Million – 5 Rounds | null | null | 3 | 4 | 4 | 5 | 3 | 3 | 4 | 5 | 4 | 5 | 5 | 5 |
Olive AI is a healthcare AI company for automating healthcare operations through advanced robotic process automation (RPA) and AI technologies. Founded in 2012 and established in Columbus, Ohio, Olive plans to eliminate repetitive tasks and improve operational efficiency for healthcare providers, this will allow staff to focus more on patient care and less on administrative duties. Olive’s mission is to essentially reduce healthcare costs and improve patient outcomes by integrating intelligent automation across healthcare systems. | https://oliveai.com | Private | “AI Workforce Built Specifically for Healthcare” | Columbus, Ohio, USA | 2012 | Drive Capital, General Catalyst, Ascension Ventures | Growth, Hypergrowth, Pivot, Winddown, For sale, Bankrupt, etc | Olive provides intelligent automation solutions designed specifically for healthcare operations, including claims management, patient scheduling, and revenue cycle management. Olive’s AI platform leverages machine learning and robotic process automation to streamline administrative tasks. | Healthcare organizations face inefficiencies due to manual, repetitive administrative tasks. | AI-powered robotic automation that efficiently handles routine healthcare administrative tasks. | Olive reduces administrative workload, cuts operational costs, and enhances patient experience through automated workflows. | Subscription model, with recurring revenue based on the scope and scale of automation services provided. | Olive’s platform utilizes machine learning, NLP, and RPA technologies, integrating into existing healthcare IT infrastructures. | Olive AI successfully addresses the critical pain points of operational inefficiency in healthcare through its AI automation solutions. With it’s strong leadership, large financial backing, and a good value proposition, Olive reduces administrative burdens, allowing healthcare professionals to focus on patient care. Their targeted approach and innovative solutions have made them as a strong proponent in the healthcare AI automation space. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/ganesharvind_5717886_91337017_OliveAI_ArvindG_Spring2025_BusinessProfileFormat.docx | Healthcare Profile | In 2020, Olive ai's revenue reached $48.9M | At one point 4 billion dollars | N/A | $902 million total funding | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 5 |
Avaneer Health, founded in 2020 by top industry leaders, is dedicated to transforming healthcare through enhanced seamless data exchange and transparency. The company’s mission is to eliminate inefficiencies in healthcare by providing a secure, decentralized network that facilitates real-time data sharing among payers, providers, and innovators. This collaborative approach aims to streamline processes, reduce administrative costs, and improve patient outcomes by ensuring that critical information is accessible when and where needed. | https://avaneerhealth.com/ | Private | Simplifying the Business of Healthcare | Chicago, Illinois | 2020 | Aetna, Elevance Health, Cleveland Clinic, HCSC, IBM, PNC Financial Services, Sentara Healthcare | Growth | Avaneer Health offers Avaneer Coverage Direct™, a solution that delivers accurate, real-time health insurance coverage information by connecting payers and providers through a secure, peer-to-peer network. This approach reduces operational costs and enhances patient experiences by ensuring both parties have the latest coverage details, minimizing claim denials and administrative burdens. The company also offers a FHIR-based network that enables secure, real-time data sharing among healthcare entities. This simplifies the administrative process and ensures participants have control over their data. | Healthcare data exchange is inefficient. This leads to administrative burdens, claim denials, and delays in accessing insurance coverage information. | Avaneer Health provides a secure, peer-to-peer network and a FHIR-based platform that enables real-time data sharing between payers and providers. This ensures seamless access to up-to-date insurance and patient information. | Reduces administrative costs, minimizes claim denials, and maximizes efficiency, and thus enhances the patient and provider experience. | Subscription. Pricing details are not publicly available, but Avaneer Coverage Direct™ can save between $3.35-$5.75 per claim for providers and $1.65 per claim for payers. | Avaneer Health’s platform is built on a FHIR-based infrastructure that facilitates real-time, secure data exchange between healthcare entities. It uses blockchain technology to ensure data integrity and security. The network’s decentralized, peer-to-peer architecture allows participants to share data directly, eliminating intermediaries. Avaneer Health also employs services like Amazon S3 for content delivery and AWS for a scalable cloud infrastructure. | Avaneer Health is a success. They have positioned themselves as a transformative force in healthcare data exchange by tackling interoperability inefficiencies (through their decentralized, peer-to-peer network built on FHIR and blockchain), acquiring strong industry partnerships, and having a clear value proposition. Furthermore, its subscription model ensures scalability and reduces administrative burdens and claim denials. More importantly, its main service Avaneer Coverage Direct™ has shown great value, saving between $3.35-$5.75 per claim for providers and $1.65 per claim for payers. The company also acquired $50 million in its seed funding round from major healthcare organizations. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/gutierrezeduardo_5613693_91263962_Business Profile_ Healthcare.docx | Healthcare Profile | Estimated Revenue of $5.7M per year. | N/A | N/A | Seed Round: $50 Million | Estimated Operating Margin: Between -20% and -50% | N/A | 5 | 4 | 5 | 4 | 2 | 4 | 3 | 5 | 4 | 5 | 5 | 5 |
Hinge Health is a digital healthcare platform that provides services intended to facilitate the treatment of musculoskeletal pain. The platform is available for both individual and organizational use, where employers can provide the platform’s services to employees at no cost. This feature allows for better employee health and higher retention and performance rates. The purpose of the application is to extend traditional physical therapy, by allowing individuals to meet with health professionals at their desired time and location, to take control of their pain and overall health. Users can simply connect with a physical therapist through a mobile application on their schedule. Within the application, users can access exercises that are designed by AI and demonstrated by professionals. Users receive real-time feedback and guidance on their techniques and approaches to exercises. Users can also meet directly with a care team to learn about their conditions, allowing them to set goals and stay on track. Hinge Health is dedicated to ensuring inclusive care for all which is why users have access to comprehensive care teams such as those in acute injuries, chronic pain, women’s pelvic health, pre- and post-surgery, and fall prevention. Users are also able to access a wearable device, known as Enso, which is FDA-cleared and calms MSK pain in minutes so members can receive drug-free pain relief. | www.hingehealth.com | Private | Let’s Get Moving! | San Francisco, CA | 2014 | Duke Capital Partners, Alkeon Capital Management, Breton Capital Ventures, Industry Ventures, etc. | Generating Revenue/Not Profitable, In IPO Registration, Venture Capital-Backed | Aimed at treating musculoskeletal pain, Hinge Health provides a range of services to users. Ranging from on-demand care, health tips, exercise recommendations, and a wearable device. While the platform is completely digital, users can scroll through personalized health plans and exercise routines, tailored to their pain and needed care. Users can set up 1-1 appointments with certified professionals at any time of the day from their given location, where they can receive trusted advice on their health plan at no cost and can even be given wearable devices for drug-free pain relief. A competitive offering of Hinge Health is their partnership with employers and insurance plans, as they can provide these services for free to users. | Access to health care professionals in the physical therapy industry can treat musculoskeletal pain. | A mobile application with an easy-to-use interface and 24/7 accessibility to medical professionals and health advice. | Effective, accessible, professional, & personalized care treatments for all individuals and all pain types, for health control. | Annual subscriptions, partnered with 2,200+ companies, charged based on customer use, free to users but uses B2B model with employers/companies | Hinge Health uses advanced AI technology to provide comprehensive digital solutions for musculoskeletal pain. AI software is used within the Enso device for personalized pain-relief simulation and is used to track user motion when conducting exercises. This AI technology shows the medical professionals if exercise movements are done correctly, allowing them to provide feedback to patients. Additionally, Cisco Webex Meetings are used for audio, video, and web conferencing when it comes to the 1-1 meeting between providers and users. Cisco serves as a core provider to Hinge Health as the company’s main purpose relies on accessibility and digital communication. | Hinge Health is a successful company because of their partnerships with over 2000 companies and health plans, allowing them to work with employers to generate revenue. Through these partnerships, they are then able to offer employees treatment at no cost. Treatment plans which are personalized and effective as they are curated with the use of AI and certified professionals, ensuring users can take control of their health and remain informed. Additionally, the accessibility of the mobile application is extremely convenient as users do not have to worry about fitting appointments into their busy schedules. Instead, employees can get in contact with medical professionals at any time of the day from any location, which increases access to care and reduces chronic pain. Outside of employer partnership, the platform is also convenient for individuals looking for exercise recommendations and real-time guidance and feedback from medical professionals which they may otherwise have difficulty getting in touch with. The devices offered for pain relief are also desirable by many as they are FDA approved and are a drug-free alternative for pain relief. Aside from the services offered to users, I think the company has also succeeded due to strong leadership. Almost all individuals found on the c-suite team of Hinge Health have graduated from prestigious universities like Oxford and Duke and have pursued higher education up to master’s and PhD programs. In addition to education rates, the individuals all have previous experience at top companies like Google or have served in other c-suite positions providing them with experience they can apply to Hinge Health. The company’s leadership includes professionals who understand the medical field and business operations, which has led to tremendous success and the process of now going public. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/hassanyara_5727837_91338241_Spring2025_BusinessProfileFormat (Healthcare AI).docx | Healthcare Profile | 300M | N/A | N/A | $827.57M | N/A | N/A | 5 | 4 | 3 | 4 | 3 | 4 | 2 | 5 | 4 | 5 | 5 | 4 |
Ada is a global digital health company dedicated to improving human health through AI-driven medical guidance. Founded by doctors, the company leverages advanced technology to bridge the gap between medical knowledge and accessible healthcare. Ada's mission is to empower individuals and healthcare professionals with personal and accurate symptom analysis, enabling informed decision-making and prompt medical attention. Ada operates at the intersection of AI and healthcare, providing solutions for individuals, healthcare providers, insurers and governments. With over 13 million users and 32 million completed assessments, Ada’s platform enhances diagnostic efficiency, patient triage and cost reduction in global healthcare systems. | https://ada.com/ | Private | Health. Powered by Ada. | Berlin, Germany | 2011 | Paul Wicks, Torsten Winkler, William Tunstall-Pedoe, Jurg Eckhardt | Growth | Ada Health offers AI-powered healthcare solutions designed to enhance accessibility and efficiency in medical services. Its core product, the Ada symptom assessment app, helps users analyze their symptoms and receive personalized health insights. Additionally, the company provides enterprise solutions that support triage, patient management and cost optimization for healthcare providers, insurers and governments. By leveraging AI, Ada supports early diagnosis, care navigation and digital health integration. | Ada Health seeks to address the gap in accessible and reliable healthcare guidance, helping users understand their symptoms and navigate the healthcare system efficiently. | Ada Health utilizes AI-driven technology for symptom assessment, analyzing user inputs to offer personalized health insights and guide them to appropriate medical care. | Ada Health offers an AI-powered symptom assessment app for individuals to manage their health, and offers enterprise solutions to partners aiming to improve healthcare services. | Ada Health follows a B2B and B2C business model, offering its AI-powered symptom assessment tool through subscriptions, partnerships and API integrations. | Ada Health leverages AI and machine learning (ML) to power its symptom assessment and clinical decision support systems. By combining natural language processing (NLP) with a medical knowledge base, the platform accurately interprets users input. Ada’s backend is built on cloud-based infrastructure for scalability and real-time data processing, ensuring fast and secure interactions. Additionally, Ada also integrates API solutions for seamless integration with healthcare providers, insurers and digital health platforms, making AI-driven health assessments widely accessible. | Ada Health's success is driven by its AI-powered symptom assessment, which provides users with quick and reliable health insights while seamlessly integrating with healthcare providers and insurers. With millions of downloads in over 130 countries, strong partnerships and a focus on clinical accuracy, Ada has positioned itself as a leader in digital health. Its research-focused approach and continuous AI advancements ensure credibility, user trust and long-term growth in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/hatakkajulie_5794665_91319875_H8 - Ada Health.docx | Healthcare Profile | Estimated revenues: $75M | null | N/A | Funding Rounds: 5 | null | null | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 4 | 4 | 5 | 4 | 5 |
Alignment Healthcare was founded in 2013 and is a healthcare company focused on providing customized healthcare services to seniors through Medicare Advantage plans. The company emphasizes a patient centric approach that leverage technology and data analytics to improve health outcomes and streamline care coordination. By integrating clinical care with personalized support, Alignment Healthcare aims to offer a more effective and compassionate healthcare experience for the aging population. | https://www.alignmenthealth.com/ | Public company | New Era of Aging | Orange, California, USA | 2013 | Blackrock, T. Rowe Price Investment Management | Growth | Alignment Healthcare provides Medicare Advantage insurance plans that include 24/7 virtual care access, in-home visits, wellness programs, prescription delivery, and a concierge style support service called ACCESS On-Demand Concierge. Through its Care Anywhere program, high risk members receive in home clinical visits. Their proprietary Alignment Virtual Application platform helps predict patient risks and coordinates care efficiently. | Seniors often face fragmented, impersonal care systems with limited access and high costs, especially those with chronic or complex conditions. | Alignment delivers integrated, tech-driven healthcare with 24/7 support and personalized care coordination to improve senior health outcomes. | Alignment delivers compassionate, coordinated, and data driven healthcare services that empower seniors to live healthier and more vibrant lives. | Alignment Healthcare offers Medicare Advantage plans and receives fixed monthly payments from Medicare to provide comprehensive healthcare services. This model encourages the company to focus on preventive care and efficient resource use that aims to improve health outcomes while controlling costs. | Alignment Healthcare utilizes AVA, a technology platform that integrates real time data and predictive analytics to enhance patient care. AVA allow care teams to anticipate health issues and coordinate timely interventions to improve outcomes for senior members. | Alignment Healthcare is redefining senior care by offering personalized Medicare Advantage plans that integrate technology, data analytics, and compassionate service. Despite current financial losses due to strategic growth investments, the company's innovative approach positions it well to capture a significant share of the senior healthcare market. As Alignment Healthcare continues to expand its offerings and national footprint, it remains committed to its mission of improving health outcomes and reducing costs for the senior population. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/jiangkevin_5665005_91337942_Spring 2025 Business Profile Format Healthcare.docx | Healthcare Profile | Approximately $2.7 billion in 2024 | 3.38 billion | NASDAQ: ALHC, 17.61 USD per share | Raised approximately $375 million prior to its IPO | Approximately -7.01% | null | 4 | 3 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 5 |
Enlitic operates as a healthcare AI company dedicated to managing medical imaging data for radiology workflow enhancement through standardized data management. The company started operations in 2014 by developing AI solutions for diagnostic support before moving to data management in radiology. Enlitic functions to “revolutionize healthcare through AI and data to support evidence-based decisions while advancing research and healthcare service delivery”. The platform at hospitals and imaging centers utilizes artificial intelligence to process imaging data which results in quicker accurate diagnoses and easier AI tool implementation in clinical settings. | enlitic.com | Public (ASX: ENL) | “Intelligence that cares.” | Fort Collins, Colorado, USA | 2014 | DCVC, Amplify Partners, Capitol Health, Thorney Investment Group, Marubeni Corp., etc | Growth | Enlitic provides its users with AI-driven tools to optimize medical imaging data management processes. The ENDEX system standardizes inconsistent DICOM metadata to achieve precise image labeling and display and the ENCOG system removes protected health information to support safe data sharing and research activities. Migratek provides efficient large-scale imaging archive migration services through Enlitic’s acquisition of Laitek technology. The solutions operate through Ensight which provides a complete data management system that automates organization processes and quality checks and governance tasks to produce a clean imaging layer suitable for clinical use and AI integration. | Radiology departments face challenges due to inconsistent and isolated imaging data which creates workflow interruptions. The lack of standardized labels or incomplete metadata on patient scans results in two major problems: hanging protocols become unusable and studies get incorrectly routed. Moving decades of legacy images between systems costs a lot of money and creates numerous errors while strict privacy rules make data sharing extremely challenging. The current issues result in wasted radiologist time while placing additional burdens on IT staff to resolve manual problems and prevent the implementation of AI tools that need properly structured data. | The data challenges are solved by Enlitic through its AI-driven data infrastructure platform. The platform automatically standardizes imaging metadata while cleaning and anonymizing the data and enabling smooth system migrations. The application of machine learning enables Enlitic to identify different exam types while creating a standardized ontology for all images to communicate throughout the organization. The system integrates into current PACS/VNA environments and cloud archives to continuously process incoming studies while removing identifying details. The end-to-end system provides a single secure data pipeline which functions alongside diagnostic AI algorithms and additional applications. | The platform from Enlitic enhances radiology workflow operations by boosting capacity and efficiency, resulting in time and money savings. Radiologists can recover their time which previously went into solving hanging protocol issues and prior examination searches. IT administrators need to spend less time performing manual data cleanup while they can quickly implement new AI models in practice. Health systems obtain better data quality which results in standardized diagnoses while making data analytics more accessible and generates additional revenue streams by using curated data for research collaborations and AI model development. Enlitic achieves digital transformation speedup and protects against legal and privacy risks through its automated PHI removal system which ensures compliance. Enlitic provides hospitals with both high-quality data and accelerated workflows that result in enhanced patient care and greater financial returns. | Enlitic functions as a B2B software company that generates revenue through recurring payments. The company offers its platform through healthcare provider subscriptions which include annual SaaS fees for ENDEX/ENCOG/Ensight usage alongside one-time services fees for Migratek migrations. The subscription-based system has been designed to produce continuous ARR. Enlitic focuses its business model on large hospital systems and imaging networks as well as private radiology groups because these entities handle extensive imaging data that requires standardization. | The technology from Enlitic uses advanced machine learning to process medical imaging data while it automatically standardizes metadata and removes personal information while maintaining clinical quality standards. The AI models of this system achieve reliable results across numerous imaging datasets because they receive training on millions of diverse medical studies. The platform connects to PACS and cloud systems through DICOM and API protocols to process imaging data in real time by standardizing and tagging and anonymizing it before secure storage or downstream applications. Enlitic operates in both on-premise and cloud environments to support scalable deployments and partners with GE Healthcare for their AWS-based imaging suite. | The healthcare AI sector now recognizes Enlitic as essential because the company focuses on image data standardization which represents the critical bottleneck slowing down both radiology workflows and AI deployment in the sector. Enlitic utilizes its AI platform to simplify data processes which results in reduced diagnosis times and streamlined system conversions together with better regulatory fulfillment.
Enlitic has earned its place in the market through its well-defined business model and unique service offering alongside its adoption of new diagnostic areas that were experiencing market saturation. The company's approach receives initial support from major partners including GE HealthCare. The ongoing financial difficulties along with growth hurdles do not thwart Enlitic from becoming an essential component for digital medical imaging infrastructure. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/jicharliechengjie_LATE_5612424_91339953_Futurist Medical AI Company Reviecw - Enlitic.docx | Healthcare Profile | $1.9 million (2024) | $30–35M (yahoo finance) | ASX:ENL, A$0.075 per share now, 52 week low A$0.0490 and 52 week high A$0.6500 | IPO | Negative operating margin | null | 4 | 3 | 5 | 4 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 5 |
Benchling was initially founded by Sajith Wickramasekara (CEO) and Ashu Singhal (President) in 2012 when they were in MIT. The founders had an academic lab where they believed that technology was not keeping up with the rate that science was changing. Their focus is a cloud-based platform to simplify scientific processes by have one place for experimental design, data management and collaboration.
The focus of Benchling is to improve biotechnology and standardize data that is produced from lab. Their main three focuses are “centralization, standardization, and automation”. Centralization of data is data in one place, standardized of data makes data stick to a specific form, and automated data captures data automatically. They also aim to integrate AI to address any shortcomings in the lab processes and simplify analysis. | https://www.benchling.com/ | Private | "Unlock the power of biotechnology." | San Francisco, California, USA | 2012 | Altimeter Capital, Franklin Templeton, Tiger Global Management, Lone Pine Capital, and more | Growth | Benchling offers a lot of products to simplify the biotech research process. The first thing it offers is an online notebook that is used in documentations. They also have tools for analyzing DNA, RNA and protein structures. They offer a registry to track cells and well as plasmids. They also offer an area to document inventory, as well as an area that provides data visualizations tools. Overall, their tools are cloud based and provide ease to the research process. | In general, Biotechnology research is a process that is inefficient and is not very organized. Currently most research uses an unadvanced method of managing data and analyzing it. | The main solution offered is a cloud platform to have a one stop shop for managing data, allowing for seamless collaboration and being as efficient as possible. | The value proposition of Benchling is that it allows a single platform to handle data management and analysis and simplify and organize the research process. | Benchling operates with a freemium SaaS model. This means that it has a free model for academic and industry researchers. However, for those who are not in this category they offer a subscription-based model where they are able to provide specific to those in different areas of life sciences. They have worked with everyone from small startups to large multinational corporations. As of May 2024, Benchling had hit an ARR of $210 million with 1.2K customers, with an average contract value of $175k per customer. | Benchling uses cloud computing to have a platform for data management. This also allows for them to scale with ease. Their main tools include an electronic lab notebook, laboratory information management system as well as data visualization and analysis tools. They have additional technology in place to make sure the data is as secure as possible. | Benchling is a biotechnology R&D company founded by MIT students Sajith Wickramasekara and Ashu Singhal. They saw inefficiencies in research processes and saw an opportunity to improve data management and analytics. They offer a subscription-based service to their clients as well as a freemium model.
Benchling offers cloud-based tools to enhance collaboration and efficiency. Tools they offer include an electronic lab notebook, design tools, workflow automation, and analytics tools. These tools enable biotech companies, academic researchers, and pharmaceutical firms to accelerate innovation.
Benchling has had strong financial growth and investment. As of May 2024, Benchling had hit an ARR of $210 million with 1.2K customers, with an average contract value of $175k per customer. They have also worked with a diverse group of companies including small startups and large corporations and continue to grow their client base. The company continues to push the boundaries of scientific research and pave the way for biotech companies. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/karivedasrihitha_5616975_91300199_Spring2025_BusinessProfileFormat (1).docx | Healthcare Profile | $210M in annualized recurring revenue (ARR) in May 2024 | Benchling was valued at $6.1 billion as of 2024 | null | The company has raised $412 million in total funding across 11 funding rounds | Benchling likely has gross margins in the 60-70% range | null | 5 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | 5 |
Tempus is a technology company dedicated to advancing precision medicine through the practical application of artificial intelligence in healthcare. Founded in 2015 by Eric Lefkofsky, Tempus aims to revolutionize healthcare by empowering healthcare providers with cutting-edge tools and insights to improve patient outcomes. The company's mission is to harness the power of data and technology to personalize treatment plans and accelerate research. Tempus is at the forefront of leveraging AI algorithms and machine learning to analyze vast amounts of clinical and molecular data. This approach enables the company to uncover patterns and insights that inform more targeted and effective treatment strategies. Tempus collaborates closely with healthcare providers, researchers, and pharmaceutical companies to tailor its solutions to meet specific stakeholder needs, driving innovation and improving patient care. | https://www.tempus.com/?srsltid=AfmBOoqxUHU-gYmx2QTGAb-7CWs5_DisYZ-Sn3OoYRmyOft5TSrOSmTc | Public | AI-enabled precision medicine | Chicago, Illinois | 2015 | Personalis, Akrivia Health, 8Trip, Exicure | Growth | Tempus offers a comprehensive suite of products and services designed to advance precision medicine through the integration of artificial intelligence and data analytics. The company's primary offerings include genomic testing services, such as next-generation sequencing diagnostics, which provide detailed molecular insights for personalized treatment plans. Additionally, Tempus provides data and services for drug discovery and development, including its Insights and Trials platforms, which leverage a broad network of physicians to facilitate clinical trial matching and research collaborations. The company also offers AI-enabled solutions like Hub and Lens, proprietary software tools that allow healthcare providers and researchers to interact with the Tempus Platform and access its vast data library for enhanced clinical decision-making and research. | Solves the problem of inefficient and less personalized healthcare. | Leveraging artificial intelligence to analyze vast amounts of clinical and molecular data, enabling more targeted and effective treatment strategies. | Ability to revolutionize healthcare by harnessing the power of data and technology to provide personalized treatment options. | Revenue channels: Partnership Fees: Tempus forms long-term alliances with hospitals, clinical centers, pharmaceutical companies, and patient advocacy groups. These collaborations involve knowledge exchange, research funding, technology integration, and data sharing agreements, generating income through one-time set-up fees, milestone payments, royalties, licensing revenues, or regular service fees. Data Analytics Services: Tempus offers access to its vast data insights through annual subscriptions or per-use arrangements. Health Economics Research: Tempus conducts cost-effectiveness analyses and comparative effectiveness studies, monetizing its expertise by consulting with government agencies, private payers, and provider networks. Metrics: Revenue Growth: 30% year-over-year revenue increase to $693 million in 2024 Gross Margins: Non-GAAP Data and Services gross margin reached 72.4% in Q2 2024 Projection: Expected to turn positive in 2025 with a projected $5 million for the full year | Tempus leverages a robust technology stack centered around artificial intelligence (AI) and machine learning (ML) to advance precision medicine. The company's Tempus Platform integrates various data types, including genomic, clinical, and imaging data, to provide actionable insights for healthcare providers and researchers. Tempus utilizes Large Language Models (LLMs) to analyze unstructured data, enhancing clinical care and research. Additionally, the company employs proprietary software tools like Hub and Lens, which facilitate interaction with the Tempus Platform and access to its vast data library. Tempus also develops AI models and algorithms, such as the Tumor Origin algorithm, to predict cancer origins and guide personalized treatment decisions. | Tempus AI's success can be attributed to its innovative approach to precision medicine, leveraging artificial intelligence to analyze vast amounts of clinical and molecular data. This enables healthcare providers to make more informed decisions, leading to improved patient outcomes. The company's strong leadership under Eric Lefkofsky has been instrumental in driving its mission forward, while its robust business model and strategic partnerships have facilitated rapid growth. A key factor in Tempus AI's success is its ability to differentiate itself through cutting-edge technology and a comprehensive data library. This differentiation allows the company to offer unique solutions that address specific needs in the healthcare sector, particularly in oncology and other complex diseases. Additionally, Tempus AI's timing in entering the precision medicine market has been advantageous, capitalizing on the growing demand for AI-driven healthcare solutions. Tempus AI's resilience and adaptability have also played crucial roles in its success. The company has continuously innovated and expanded its offerings to meet evolving customer needs and stay competitive in a rapidly changing healthcare landscape. Overall, Tempus AI's success is a testament to its commitment to innovation, customer satisfaction, and strategic growth strategies. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kimgeoffrey_5627721_91337127_Spring2025_BusinessProfileFormat (Tempus).docx | Healthcare Profile | Approximately $693.4 million | $8.84B | Stock Symbol: TEM (NASDAQ) Current Stock Price: $48.03, 52-Week High: $91.45 USD, 52-Week Low: $22.89 USD | Total of $1.345 billion over 12 funding rounds
IPO (June 2024): $410.7 million | -99.66% (2024) | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | -1 | 4 | 5 | 5 | 5 |
Nabla is a French startup specializing in AI-driven solutions for the healthcare industry. Their flagship product, Nabla Copilot, is an ambient AI assistant designed to alleviate the administrative burden on healthcare providers and reduce clinician burnout. The tool listens to clinical consultations and drafts notes summarizing key elements, such as patient medical history, symptoms, diagnoses, and prescriptions. Nabla has raised significant funding, including a $24 million Series B round, to expand its capabilities and adoption. The company has seen rapid growth, with over 20,000 providers adopting Nabla Copilot, and has formed strategic partnerships, such as with Kaiser Permanente, to further its reach and impact in the healthcare sector. | www.nabla.com | Private | The medical assistant that frees up your time | Paris, France | 2018 | Venture Capital-Backed | Generating Revenue | Nabla offers innovative AI-driven solutions tailored for the healthcare industry. Their flagship product, Nabla Copilot, is an ambient AI assistant designed to streamline clinical workflows and reduce administrative burdens on healthcare providers. By listening to clinical consultations, Nabla Copilot generates comprehensive and accurate notes that capture essential details such as patient history, symptoms, diagnoses, and treatment plans. This tool enhances the efficiency and accuracy of medical documentation, allowing clinicians to focus more on patient care. Additionally, Nabla provides platforms for direct communication between patients and healthcare professionals, further improving accessibility and quality of care. The company's solutions are built to integrate seamlessly into existing healthcare systems, making them accessible and beneficial for a wide range of medical practices and institutions. | Doctors spend excessive time on administrative tasks, reducing time spent on patient care and leading to burnout. | Nabla Copilot uses AI to transcribe patient conversations and generate structured clinical notes, integrating seamlessly with EHR systems. | Nabla reduces documentation time by up to 50%, allowing doctors to focus more on patient care, reduce burnout, and improve work-life balance. It enhances efficiency and accuracy in clinical documentation. | Subscription-based model with potential per-use pricing for additional features or services. | The tech stack likely includes advanced natural language processing (NLP) models, possibly leveraging GPT-3 or similar technologies, integrated with secure cloud infrastructure for data handling. The system is designed to ensure HIPAA compliance for protecting patient data, with user-friendly interfaces built using modern web development frameworks for seamless integration into existing clinical workflows. | Nabla has emerged as a pioneer in the healthcare technology sector with its groundbreaking ambient AI assistant, designed to revolutionize the way medical practitioners handle administrative tasks and enhance patient care. By harnessing the power of advanced natural language processing (NLP) and artificial intelligence, Nabla offers a seamless solution that transcribes doctor-patient conversations in real-time, generating comprehensive and structured clinical notes. These notes are automatically integrated into Electronic Health Record (EHR) systems, significantly reducing the time and effort traditionally spent on documentation.
The company's innovative approach addresses a critical need in the healthcare industry, where practitioners often face burnout due to the overwhelming administrative burden. Nabla's technology not only streamlines workflows but also ensures accuracy and efficiency in clinical documentation, allowing healthcare professionals to dedicate more time to direct patient care. This shift has the potential to improve patient outcomes by enabling more focused and attentive interactions between doctors and patients.
Nabla's success is underpinned by its strong commitment to data privacy and compliance with healthcare regulations, ensuring that sensitive patient information is handled securely. The platform's user-friendly design and ease of integration with existing systems have made it a favored choice among medical practitioners, further solidifying its position in the market.
Led by a team of experienced entrepreneurs, engineers, and physicians, Nabla continues to push the boundaries of AI-driven healthcare solutions. The company's strategic focus on continuous innovation and customer-centric development has enabled it to stay ahead in the rapidly evolving healthcare technology landscape. With a clear value proposition and a robust technological foundation, Nabla is well-positioned to lead the transformation of medical practice, making it more efficient, effective, and patient-focused.
As Nabla continues to grow and expand its offerings, it remains dedicated to improving the quality of care and the lives of healthcare professionals, ultimately contributing to a more sustainable and resilient healthcare system. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kostlouis_5786705_91298810_Nabla_BusinessProfileFormat_Louis.KOST.docx | Healthcare Profile | null | $120.43M | Not publicly traded | $53.94M | null | Not publicly traded | 4 | 5 | 3 | 5 | 2 | 3 | 3 | 5 | 2 | 5 | 5 | 4 |
GRAIL is a healthcare company focused on catching cancer early—before it becomes hard to treat. They’ve developed a cutting-edge blood test that can detect cancer signals from over 50 types of cancer, even before symptoms appear. By using advanced sequencing and AI-driven analysis, GRAIL aims to make early detection more accurate, accessible, and routine, ultimately saving lives and reducing healthcare costs. | https://grail.com | Public | Detecting Cancer Early, Transforming Lives | Menlo Park, California, USA | 2015 | Illumina, CPP Investments, Huangpu River Capital, PSP Investments | Generating Revenue / Not Profitable | GRAIL’s flagship product, Galleri, is a groundbreaking multi-cancer early detection (MCED) test capable of identifying signals from over 50 types of cancer through a simple blood draw. The company also provides clinical studies, data analysis, and genomic research to further improve early cancer detection technology. | Late-stage cancer diagnoses significantly reduce survival rates and increase treatment costs. Current screening methods are limited to a few cancer types and fail to detect many cases early. | GRAIL’s Galleri test detects cancer at earlier stages by analyzing cfDNA (cell-free DNA) in blood, reducing the reliance on late-stage diagnostics. | Early cancer detection saves lives, reduces healthcare costs, and enables proactive treatment strategies, making widespread screening feasible and effective. | GRAIL operates on a B2B and B2C model, offering its Galleri test to healthcare providers, insurers, employers, and directly to consumers. Revenue is generated through test sales, subscription-based screening programs, and partnerships with health organizations. | GRAIL employs high-intensity sequencing, AI-driven data analysis, and machine learning algorithms to identify and classify cancer signals in cfDNA. | GRAIL, Inc. is a healthcare company specializing in early cancer detection through its Galleri® blood test, which screens for over 50 types of cancer. Using advanced genomic technology and AI, GRAIL aims to improve early diagnosis and reduce cancer mortality. Recently spun off from Illumina and now trading independently, GRAIL continues to expand its market reach and clinical validation efforts. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kupkaamalie_5794043_91316536_Business Profile - GRAIL.docx | Healthcare Profile | 2024: 125,595 | $942.63M | Now: $27.81, 52 week low: $12.33, high: $63.99 | 5 rounds, $2B | 0.00% | -0.4038 | 4 | 3 | 5 | 4 | 3 | 4 | 5 | 5 | 3 | 5 | 4 | 5 |
Aidoc is a health tech startup on integrating Ai to medical imaging and radiology. The company develops Ai-based decision-support software that analyzes medical images in real-time to detect and flag conditions such as strokes, pulmonary embolisms, and brain hemorrhages. Aidoc's mission is to speed up diagnosis, reduce work load, at the same time improve patient outcomes by integrating Ai. | https://www.aidoc.com | Private | Always-on AI for radiology | Tel Aviv, Israel | 2016 | Square Peg, Aleph, EDBI, General Catalyst | Growth | Aidoc offers FDA cleared AI-powered solutions that run in the background as radiologists work, identifying anomalies and prioritizing life-threatening cases. The product supports multiple pathologies across the body and integrates into existing PACS systems, improving hospital efficiency and diagnostic accuracy. | Radiologists are overwhelmed by large volumes of imaging data, leading to delays in diagnosis and increased rates of burnout. | Aidoc leverages AI to automatically analyze scans in real-time, helping radiologists prioritize urgent cases and make faster, more accurate decisions. | "Accelerate time-critical diagnoses and improve patient outcomes with intelligent imaging workflows." | Aidoc uses a subscription-based SaaS model, selling its platform to hospitals and imaging centers. Customers pay a recurring fee based on the number of scans processed or active modules used. | Aidoc uses deep learning and convolutional neural networks (CNNs) trained on large medical datasets to detect pathologies. The solution integrates with existing radiology infrastructure via cloud-based APIs and complies with medical standards like HIPAA and DICOM. | Aidoc contributed to successfully integrating ML to radiology. Its real-time, always-on diagnostic feature have gained regulatory approval and are now used in leading hospitals across multiple countries. With strong funding, a focused leadership team, and proven clinical results. Aidoc Solves one of healthcare's most pressing challenges: time-sensitive diagnosis. Its adoption trajectory and product pipeline indicate a strong potential to scale. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/leejoonsung_LATE_5794341_91419259_Readings and Healthcare AI_ co business profile.docx | Healthcare Profile | Estimated $40–50M annually | null | null | $140Mil | null | Not applicable | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 5 | 5 | 4 | 4 |
Verge Genomics is a San Francisco–based startup focused on transforming drug discovery through artificial intelligence and advanced genomics. Founded in 2015, Verge Genomics applies machine-learning methods to identify new therapeutic targets for challenging neurological diseases such as ALS and Parkinson’s disease.
The company’s mission is to accelerate the discovery of life-saving therapies by integrating genomic data, cutting-edge computational models, and laboratory validation. | https://www.vergegenomics.com | Private | “Accelerating cures for complex diseases with AI” | San Francisco, California | 2015 | ALS Investment Fund, DFJ, Wuxi AppTec, others | Growth | Verge Genomics’s primary offerings revolve around its AI-driven drug discovery platform, which integrates large genomic datasets and computational models to identify potential drug targets more efficiently. It collaborates with pharmaceutical companies and develops its own early-stage pipeline of drug candidates. | Traditional drug discovery is time-consuming, expensive, and has a high failure rate, especially in complex diseases such as neurological disorders. | An integrated platform that uses machine learning and genomic data to pinpoint the most promising therapeutic targets, helping to reduce time and cost in preclinical research. | Verge Genomics reduces the costs, risks, and timelines inherent in traditional drug discovery by combining large-scale genomic data, sophisticated algorithms, and a proprietary validation framework. | Verge Genomics partners with pharmaceutical companies in co-development deals and also develops in-house drug candidates for eventual licensing or acquisition. Revenue can come from milestone payments, licensing fees, and royalties from successful therapies. | Verge Genomics employs a proprietary AI/ML platform that analyzes large datasets of patient genomic information, identifies disease-relevant gene networks, and predicts the likelihood that a particular drug candidate will be effective. This tech stack includes:
Machine learning models for analyzing transcriptomic and genomic data
Cloud computing for large-scale data processing
Proprietary algorithms to rank potential drug targets
In-house wet-lab capabilities for validating computational predictions | Verge Genomics stands out in the AI-driven drug discovery sphere by focusing on complex neurological diseases, an area where traditional methods face significant obstacles. Their integrated approach—merging genomics data with machine learning—allows them to prioritize the most viable drug targets and streamline preclinical testing. This strategy appears promising, as evidenced by venture capital interest and partnerships with established pharmaceutical firms.
Although still in a growth phase, Verge’s leadership and scientific team have a strong vision that appeals to collaborators and investors. The core value they bring lies in accelerating the pace of drug discovery while reducing costs, which, if successful, could lead to transformative treatments for diseases with few existing therapies. By leveraging AI to inform decision-making, Verge Genomics has the potential to reduce the high risk and attrition rates plaguing drug development, positioning the company as an emerging leader in AI-powered healthcare innovation. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/leemichelle_LATE_5618088_91361550_Verge Genomics.docx | Healthcare Profile | Not publicly disclosed (private company) | N/A (private) | N/A (private) | Over $50 million in venture funding (Series A, B) | N/A (R&D–focused startup) | N/A (not publicly traded) | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 4 | 3 | 5 | 4 | 5 |
Radiology Partners is among the biggest physician owned and physician led radiology practices in the nation, practicing at hundreds of hospitals and healthcare facilities across the country. With the vision of transforming radiology through quality care, innovation, and service, the company has keen focus on clinical excellence, superior service, and physician leadership. Radiology Partners fosters a collaborative approach that allows radiologists to shape change, drive improvement in patient outcomes, and advance healthcare delivery.
The company is committed to elevating the practice of radiology through a technology based platform and a strong emphasis on research, data analysis, and AI. With a national footprint and a strong local footprint in each of its markets, Radiology Partners provides integrated imaging services while being sensitive to the unique needs of each customer. Their core focus on quality improvement, operational efficiency, and patient-centered care has made them a leader in scaling radiology transformation. | https://www.radpartners.com/ | Private | Focused on our patients. Led by our physicians. Driven by our mission. | El Segundo, CA | 2012 | Buyout/LBO by Advanced Radiology, SC | private equity backed | Radiology Partners is a leading provider of teleradiology, onsite imaging services to hospitals, outpatient facilities, and imaging centers. They provide imaging services including x-ray, CT, MRI, ultrasound, and nuclear medicine. They also provide a variety of clinical support services including quality assurance, peer learning, and operationalizing radiology workflows. They use machine learning with AI solutions to increase diagnostic accuracy and reduce turnaround times trained from well trained and experienced radiologists. | Radiology Partners addresses the problem of inconsistent radiology services and a national shortage of radiologists, which may result in delays in diagnosis, variation in quality, and decreased access to subspecialty knowledge. | Radiology Partners offers a scalable, physician-led radiology practice that blends national resources with local clinical expertise, state-of-the-art technology, and subspecialty availability to deliver consistent, high-quality imaging services not backed by high quality resources or specialists. | Radiology Partners offers collaborative radiology services through an innovative platform that allows physicians around the nation give quality information about their radiology questions and concerns. | Service/subscription based | Radiology Partners has a robust technology platform constructed upon advanced imaging systems, artificial intelligence (AI), and cloud-based workflow environments for enhancing diagnostic accuracy and streamlining radiology functions. The technology consists of AI-assisted image evaluation and clinical decision support technologies coupled with picture archiving and communication systems and radiology information systems to allow transparent data exchange and reporting. | Radiology Partners is a successful physician led imaging service that offers collaborative resources to help other physicians with radiology/imaging needs around the nation. The physician based service highlights the importance of having primary care physicians involved during the process to offer unmatched care and quality of its services. Their use of transformative technology like machine learning and AI is boosting their precedence in the sector by developing more timely and quality imaging services compared to others.
The growth of Radiology Partners due to their strategy of affiliation, with hospitals, outpatient, and health systems has been remarkable but still in the boundaries of providing patients good value. Their focus and priority on quality assurance has truly advanced an environment for innovative and flexible practice. As a result, Radiology Partners is now clearly positioned leading the way to re-evaluate the practice of radiology to appropriately deal with the shortage of radiologists and demand for specialty imaging with the service technology that will meet those needs. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/loubrandon_LATE_5568559_91343824_Spring2025_HealthcareProfileFormat.docx | Healthcare Profile | >$2 billion | Privately held company | null | $2.12 billion over 14 rounds
Latest: $720 million in growth equity investments | 12.9% | null | 5 | 4 | 2 | 4 | 2 | 4 | 3 | 3 | 2 | 3 | 3 | 2 |
Alma is a healthcare company dedicated to improving access to high-quality, affordable mental health care by supporting therapists with tools to grow and manage their practices. Founded in 2018 and headquartered in New York City, Alma operates a digital platform that provides mental health professionals with insurance support, practice management tools, and a directory to connect with clients. The company enables therapists to accept insurance, reducing financial barriers for individuals seeking care. With substantial funding from investors like Insight Partners and Optum Ventures, Alma has expanded rapidly, emphasizing innovation and equity in mental health services. Led by CEO Dr. Harry Ritter, the company is committed to transforming the mental health care industry by making it more accessible, efficient, and provider-friendly. | helloalma.com | Private | "Helping Therapists, Helping People" | New York City, USA | 2018 | Insight Partners, Optum Ventures, Cigna Ventures, Thoma Bravo | Growth | Alma offers a comprehensive platform for mental health professionals, including practice management tools, insurance credentialing support, and client-matching services. Therapists can streamline administrative tasks, accept insurance with ease, and grow their private practices while focusing on providing quality care. For clients, Alma provides an easy-to-navigate directory to connect with therapists based on insurance, specialties, and preferences. | Mental health care is often inaccessible due to high costs, insurance barriers, and limited provider availability. | Alma bridges the gap by enabling therapists to accept insurance while providing them with business support, making therapy more affordable and widely available. | Alma enhances accessibility to mental health care by empowering providers with financial and operational tools while connecting clients with suitable, in-network therapists. | Alma operates on a subscription-based model, charging therapists a membership fee for access to practice management tools, insurance support, and directory listings. The company also earns a portion of insurance reimbursements processed through its platform. | Alma leverages cloud-based practice management software, electronic health records (EHR) integration, and AI-driven client-provider matching. Its platform is designed for scalability, offering seamless insurance billing, scheduling, and analytics. | Alma over the years has positioned themselves as a leader in the mental health sector by addressing critical issues of both accessibility and affordability. By empowering therapists and giving them business solutions by simplifying insurance processing, Alma has made notable strides in improving mental health care delivery. Their rapid growth, strong investor backing, and focus on innovation make them a standout player in the healthcare industry. With constant increasing demand for mental health services, Alma is a well-positioned company that has the power to continue scaling while maintaining their missions to enhance mental health access for all. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/lozanovillasenorsantiago_5769687_91338054_healthcare doc.docx | Healthcare Profile | null | Private company | N/A | $230M total, including a $130M Series D in 2022 | null | Not applicable | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | -1 |
SOPHiA GENETICS is a pioneering healthcare technology company that harnesses advanced data analytics and artificial intelligence to transform the way genomic and clinical data are interpreted. The company’s core mission is to democratize data-driven medicine, empowering healthcare professionals and researchers worldwide to make informed decisions with greater accuracy and efficiency.
Founded with the vision of integrating complex bioinformatics into everyday clinical practice, SOPHiA GENETICS has developed a robust platform that streamlines genomic analysis for applications in oncology, rare diseases, and beyond. By converting vast amounts of genomic data into actionable insights, they are helping to reduce diagnostic errors and accelerate personalized treatment plans.
Committed to continuous innovation, SOPHiA GENETICS leverages state-of-the-art technologies and strategic partnerships to address critical challenges in precision medicine. Its focus on scalability, regulatory compliance, and patient-centric outcomes has positioned the company as a leader in an industry that is rapidly evolving. | https://www.sophiagenetics.com | Public | "Democratizing Medicine Through Data-Driven Insights" | Lausanne, Switzerland | 2011 | Sofinnova Partners(1st), Wellington Partners, Kurma Partners, QIA | Hypergrowth | SOPHiA GENETICS offers a comprehensive AI-powered platform that supports genomic and clinical data analysis for diagnostic and therapeutic applications. Their flagship product streamlines the interpretation of complex datasets, aiding clinicians in precision oncology and rare disease diagnosis. | The overwhelming complexity of genomic data interpretation that hinders accurate and timely diagnosis. | An integrated, cloud-based platform that leverages machine learning to deliver actionable insights from genomic data, facilitating precision medicine. | Using high-quality, data-driven insights, SOPHiA GENETICS improves diagnostic accuracy, optimizes treatment plans, and ultimately enhances patient outcomes. | SOPHiA GENETICS operates primarily on a subscription-based model for its SaaS platform, complemented by usage-based pricing for clinical laboratories and healthcare institutions. The company also builds channel partnerships with diagnostic centers and hospitals. Key performance metrics include recurring revenue growth, the number of tests processed, and adoption rates among global healthcare providers. | The SOPHiA platform is underpinned by robust machine learning algorithms, secure cloud computing, and big data analytics. This technology stack allows for the rapid processing and integration of genomic and clinical datasets while maintaining compliance with stringent medical data privacy regulations. The platform’s interoperability with existing hospital IT systems and its continuous evolution through iterative improvements ensure that it remains at the forefront of precision medicine innovation. | SOPHiA GENETICS has emerged as a transformative leader in healthcare technology by tackling the critical challenge of interpreting complex genomic data. Its innovative, AI-driven platform streamlines diagnostic processes, empowering clinicians with actionable insights that enhance patient outcomes and reduce diagnostic delays. By integrating advanced analytics, cloud-based computing, and scalable machine learning, the company is democratizing access to precision medicine, ultimately driving higher standards in clinical care.
Underpinned by visionary leadership and a steadfast commitment to continuous innovation, SOPHiA GENETICS has secured a significant market share through strategic global partnerships and a robust, subscription-based business model. Its rigorous adherence to regulatory standards, effective market differentiation, and sustained operational excellence have solidified investor confidence. As the company expands its technological capabilities and market reach, it continues to set new benchmarks in precision healthcare, ensuring its role as a pivotal force in transforming modern medicine. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/manchandadivjotsingh_LATE_5795144_91345149_Business Profile - SOPHiA Genetics.docx | Healthcare Profile | $65.17M (2024, +4.49% growth) | $245.95M | NASDAQ: SOPH : $3.68 | IPO - 2021 | Negative 105% | NA - loss making | 4 | 3 | 3 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
PharmEasy is an Indian health-tech startup and online healthcare aggregator founded in 2015 that connects patients with local pharmacies and diagnostic centers for medicine delivery, diagnostics, and telehealth services. | www.pharmeasy.in | Private | To change the face of healthcare in India, one consumer at a time. | Mumbai, Maharashtra, India | 2015 | PharmEasy has raised funding from investors including Temasek and GSV | Growth | Through its platform, PharmEasy provides a full suite of healthcare solutions that encompass online prescription medicine delivery, OTC medicines, healthcare and wellness products, booking of diagnostic tests, and teleconsultation. The context for these services is a platform connecting users with local pharmacies and diagnostic centers for timely delivery of medicine and health checkups. The user experience includes subscription based healthcare plans and a B2B vertical itself for hospitals and clinics supplying medical equipment and pharmaceuticals. | Limited access to affordable medicines and healthcare services, especially in remote areas. | A tech platform for easy medicine orders, lab test bookings, and online doctor consultations. | Convenient, affordable, and accessible healthcare for everyone. | Commission-Based Sales: Charges partner pharmacies and diagnostic centers a commission per transaction. Subscription Model: Offers "PharmEasy Plus" for free deliveries and discounts. Advertising Revenue: Earns from sponsored product listings and healthcare ads. B2B Supply (VAD/VAR Model): Supplies medicines and medical equipment to hospitals and pharmacies. Fixed Price Model: | uses advanced data analytics, artificial intelligence (AI), and machine learning (ML) to optimize supply chain logistics and personalize user experiences. The mobile and web applications are built using scalable cloud technologies to achieve high availability and security. Also, PharmEasy uses secure payment gateways, and follows strict data protection practices to protect user information. | The rise of telemedicine along with a network of partnered pharmacies and diagnostic services has been essential for PharmEasy to satisfy a critical need for increasingly accessible and affordable healthcare in India, especially in light of the speed in which healthcare services moved online due to COVID-19. It has been possible for PharmEasy to quickly scale across India due to its business model that targets both B2B, B2C and subscription services to meet the needs of a broad customer base. Its technology advances, such as leveraging AI and cloud-based applications to streamline logistics and customer experience, has added competitive advantages. PharmEasy has captured the attention the investment community, attracting substantial capital to support its continued expansion into additional healthcare services, including teleconsultation. While PharmEasy has been met with significant competition and operational challenges, the company's capacity to make rapid, yet successful pivots in the digital healthcare market, along with continued resilience presents worthy pathways to sustain its position. Finally, the company has also faced hurdles in the form of declining valuation and management turnover. In addition to increasing competition and evolving regulation, these represent headwinds to its growth. Nonetheless, PharmEasy remains well positioned for continued success in the rapidly shifting healthcare context and ecosystem in India through its continued commitment to the expansion of its offerings, customer experience, technology and infrastructure. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/nrmugheshkumar_LATE_5795003_91343514_Spring2025_BusinessProfileFormat.docx | Healthcare Profile | ₹5,664 crore (-14.8% YoY) | $710M (April 2024) | Private company (Not listed) | null | Not publicly disclosed | Not applicable (Private firm) | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 5 | 4 |
Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven biotechnology company founded in 2014. The company's mission is to accelerate drug discovery and development using advanced AI technologies. Insilico focuses on connecting biology, chemistry, and clinical trials analysis using next-generation AI systems, including generative models, reinforcement learning, and other machine learning techniques. Their primary goal is to discover and develop innovative drugs for various diseases, including cancer, fibrosis, central nervous system disorders, infectious diseases, autoimmune diseases, and aging-related conditions.
The company has developed a proprietary AI platform called Pharma.AI, which consists of PandaOmics (target discovery), Chemistry42 (small molecule generation), and InClinico (clinical trial prediction). This integrated platform enables Insilico to rapidly identify novel targets, design new molecules, and predict clinical trial outcomes, significantly reducing the time and cost associated with traditional drug discovery processes. | insilico.com | Private | AI-powered end-to-end drug discovery and development | Cambridge, Massachusetts, USA | 2014 | Value Partners Group, Warburg Pincus, Qiming Venture Partners, WuXi, HongShan, Hillhouse | Hypergrowth | Insilico Medicine offers a range of AI-driven drug discovery and development services, including target identification, small molecule design, and clinical trial outcome prediction. Their flagship product is the Pharma.AI platform, which integrates various AI technologies to accelerate the drug discovery process. The company has also developed a portfolio of 30 drug candidates, with 10 receiving IND clearance. Their most advanced candidate, Rentosertib, is in Phase II clinical trials for idiopathic pulmonary fibrosis (IPF). | The time-consuming and costly process of traditional drug discovery and development. | AI-powered drug discovery platform that significantly reduces time and cost while increasing the probability of success. | Accelerating the development of life-saving therapies by leveraging AI to redefine biopharmaceutical R&D. | Insilico employs a hybrid business model, combining internal drug development with out-licensing deals and collaborations. They generate revenue through pipeline out-licensing agreements and drug discovery collaborations with industry partners. | Insilico's technology stack is built around its Pharma.AI platform, which integrates generative AI, deep learning, and large language models. Key components include PandaOmics for target discovery, Chemistry42 for small molecule generation, and InClinico for clinical trial prediction. The company also utilizes advanced robotics in its fully automated Life Star1 laboratory. | Insilico Medicine has emerged as a leading force in AI-driven drug discovery, demonstrating remarkable success in a rapidly evolving field. The company's innovative approach, combining cutting-edge AI technologies with deep expertise in biology and chemistry, has positioned it at the forefront of the pharmaceutical industry's digital transformation.
Insilico's success can be attributed to several key factors. First, its strong leadership under founder and CEO Alex Zhavoronkov has guided the company through rapid growth and technological advancements. The company's ability to secure significant funding, including a recent $110 million Series E round, demonstrates investor confidence in its potential. Insilico's differentiated approach, leveraging its proprietary Pharma.AI platform, has enabled it to dramatically reduce drug discovery timelines and costs, addressing a critical need in the pharmaceutical industry.
The company's impressive pipeline of 30 drug candidates, with 10 receiving IND clearance, showcases the effectiveness of its AI-driven approach. The advancement of Rentosertib to Phase II clinical trials for IPF further validates the company's ability to translate AI-generated discoveries into potential therapies. Insilico's hybrid business model, combining internal drug development with strategic partnerships and out-licensing deals, has created multiple revenue streams and opportunities for growth. With its continued focus on innovation and strong market positioning, Insilico Medicine is well-poised to revolutionize drug discovery and development, potentially bringing life-saving therapies to patients faster and more efficiently than ever before. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/pantianyue_5795402_91316944_Spring2025_BusinessProfileFormat_tianyue_health.docx | Healthcare Profile | $70.5M | null | null | $110M (Series E) | null | null | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 5 | 5 | 5 |
Babylon Health was a digital healthcare company that used AI and telemedicine to provide cheaper and accessible healthcare services. Babylon offered remote consultations, medical advice, and health management through its platform, making healthcare more convenient for patients and reducing pressure on healthcare systems. The goal of Babylon Health was to make healthcare available to everyone, regardless of location and financial status. Babylon connected patients with healthcare providers through video calls, offering quick and personalized care. The company aimed to improve health outcomes, reduce wait times, and make healthcare easier to access for people around the world. | https://www.babylonhealth.com/en-us | Public | ‘We’re for health, for all’ | London, UK | 2013 | Hard to list all but notable ones are Saudi Arabia’s PIF and Swedish Pension Fund | Bankrupt | Babylon Health offered many services, including AI-powered health assessments, remote consultations, and personalized health management tools. Their video consultations allowed patients to speak with healthcare providers about medical concerns. Babylon also offered a symptom checker powered by AI, prescription services, and health tracking features through their app. Additionally, the company provided health monitoring tools for managing chronic conditions, making it easier for patients to track their health and receive timely care. | Babylon solved issues of accessibility and cost in healthcare by providing telemedicine services that relieve stress on conventional hospitals and expand access. | Online platform to provide telemedicine services to patients. | Babylon’s value proposition was that their healthcare services are cheaper and faster than conventional healthcare services. | Babylon’s business model combined subscriptions, fixed-price offerings, and partnerships with healthcare providers. The subscription model provided patients with access to virtual consultations, health assessments, and health management tools. They also offered fixed-price services for one-off consultations or treatments. Babylon partnered with health insurance companies, integrating their platform into healthcare plans to expand its reach. They had over 2 million global users at their peak. | Babylon leveraged AI and machine learning technologies for its health assessments, symptom checker, and virtual consultations to analyze patient data and provide personalized medical advice. Babylon’s tech stack included cloud-based infrastructure for scalability and reliability. The platform also integrated telemedicine tools for secure video consultations and uses data analytics to monitor patient health and outcomes. | Babylon Health achieved success due to its mobile approach to healthcare, blending AI with telemedicine to create a platform that was accessible and affordable. The company’s use of AI powered providers to deliver higher quality and data driven healthcare to places where it wasn’t as accessible. Babylon scaled its services quickly, forming key partnerships with insurance companies, public health organizations, and global healthcare providers, which helped it expand its reach and build a significant user base.
Despite facing challenges such as regulatory hurdles and competition in the crowded telemedicine space, Babylon Health’s ability to innovate and address real healthcare needs positioned it for success during its operational years. However, with the shutdown, it shows that even innovative companies must navigate complex financial and operational pressures to sustain long-term growth, even when revenues are in the billions like Babylons. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/patelrushi_5610698_91296204_Spring2025_BusinessProfileFormat (1).docx | Healthcare Profile | $1.1 billion in revenue, $221 million net loss | ~300 million | Symbol: BBLNF Price currently: 0 Peak in 2021: $258 | $1.2 billion total raised in 9 rounds | null | null | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 2 | 4 | 4 | 4 |
Corti is a Danish AI company offering a voice-based platform that helps healthcare practitioners analyze patient interviews in real-time. By using advanced AI, the platform enhances decision-making during medical consultations, enabling faster and more accurate diagnoses. Corti’s customers include healthcare organizations, medical practitioners, and public safety providers who leverage its AI-powered platform to optimize patient interactions and enhance decision-making. Healthcare organizations use Corti to optimize their patient interview processes, ultimately saving time, reducing costs, and improving the overall quality of care. Corti’s mission is to empower medical professionals with innovative technology that enhances patient outcomes and ensures efficient, data-driven decision-making. With a strong focus on improving the healthcare experience, Corti aims to revolutionize how patient interactions are conducted and analyzed. | https://www.corti.ai/ | Private sector | “We are on a mission to ensure everyone has access to medical expertise, no matter where they are”. | Brooklyn, New York | 2014 | Atomico and Eurazeo are some of the investors. | Growth | Corti offers a variety of flexible products that can be used on their own, customized with an organization’s branding, or integrated into existing systems. Here are the key solutions they provide:
Ambient Scribe: Automates documentation during patient visits, saving time and increasing efficiency.
Automatic and Assisted Medical Coding AI: Improves revenue per visit, reduces claim denials, and streamlines coding workflows.
Call and Interaction Recording: Records and transcribes conversations, offering AI-driven insights to improve conversation quality.
AI-Ready Data Warehouse: Consolidates clinical, operational, and engagement data for actionable intelligence and trend analysis.
AI-Based Medical Dictation: Offers natural language dictation for accurate and automated EHR input.
Corti AI-Chat: A healthcare-focused AI chat agent that assists patients and supports providers in their workflows.
Intelligent Triage: Guides staff through protocols and questionnaires for compliant and productive triage interactions. | Healthcare practitioners spend considerable time on administrative tasks like documentation and coding, reducing time for patient care and increasing the risk of errors. | Corti’s AI platform automates documentation, coding, and patient interaction analysis, helping healthcare providers focus on patient care while improving efficiency and accuracy. | Corti helps healthcare professionals by automating tasks, improving decision-making, and streamlining processes, leading to better patient outcomes, lower costs, and more efficient workflows. | Corti operates on a subscription model, ensuring stable revenue and long-term client relationships. Key metrics include customer acquisition cost (CAC), monthly recurring revenue (MRR), customer retention rate, and lifetime value (LTV) to measure growth and profitability. | Corti uses AI, machine learning, and natural language processing to analyze patient interactions. Its cloud-based platform offers real-time processing, secure data storage, and seamless integration with healthcare systems, improving efficiency and compliance in medical workflows. | Corti is a Danish AI company that uses technology to improve healthcare. Its platform helps healthcare providers by automating tasks like documentation, medical coding, and decision-making during patient interactions. This makes healthcare work faster and more accurately. Corti is positioned well in the growing AI healthcare market and has raised strong funding to continue expanding. Their solutions are designed to help healthcare providers save time, reduce errors, and ultimately provide better care to patients. With its innovative approach, Corti is set to make a big impact in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/rostadsandsynne_5794130_91338045_Corti Company Description.docx | Healthcare Profile | $1.26 million (Gross Profit) | null | null | Number of Funding Rounds: 3
Total funding Amount: $103 million | null | null | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Butterfly Network Inc. is revolutionizing healthcare with its handheld, whole-body ultrasound powered by proprietary Ultrasound-on-Chip technology. This affordable, pocket-sized device integrates seamlessly with cloud-connected software and a mobile app, making ultrasound imaging more accessible and practical in clinical workflows.
The Butterfly iQ+ enables whole-body imaging through a single handheld probe, leveraging semiconductor technology for a compact, cost-effective, and user-friendly solution. By combining advanced imaging with digital connectivity, Butterfly is transforming ultrasound into a more convenient and widely available diagnostic tool. | https://english.butterflynetwork.com/#News | Public | Bringing the power of ultrasound into your assessment, diagnosis and treatment | 1600 District Avenue Burlington, MA 01803 United States | 2011 | Baillie Gifford
Eldridge Industries
Fidelity Management & Research Company
Glenview Capital Management
Ridgeback Capital
Tenet Healthcare | Growth | Offerings:
Butterfly Network Inc. offers a range of portable ultrasound imaging solutions designed to enhance patient care. Their product is the Butterfly iQ series, which is handheld, whole-body ulstrasound devices that can connect seamlessly with smartphones and tablets. | Making ultrasound easier | Portable ultrasound imaging | Make it easier to get an ultrasound, by making medical imaging more accessible and efficient. | Their business model combines direct sales of its ultrasound devices with subscription-based services for their software offerings. Their hybrid solution ensures a continuous revenue stream while providing customers with up-to-date tools and support. | Ultrasound-on-chip technology, which is a whole-body ultrasound device. | Butterfly Network is a success in the medical imaging industry with its groundbreaking Ultrasound-on-Chip technology. By developing a portable, handheld ultrasound device, the company has made ultrasound imaging more accessible and affordable for healthcare professionals worldwide. Butterfly´s innovation has positioned the company as a leader in the ultrasound technology, particularly in underserved and remote areas. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/saetrevanessa_5794411_91298577_Butterfly Network.docx | Healthcare Profile | 2024: 92,056 million USD
2023: 65,900 million USD | As of March 2025, 573,85 million USD | Symbol: BFLY
Current price: 2.68 USD
52 week range: 0.67-4.98 USD | On January 31th in 2025 Butterfly Network closed a public offering, getting 81,7 million USD. | In Q4 2024: gross margin of 61.4% | Not applicable, since the company reported a net loss in the latest quarter. | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 4 | 4 | 5 |
Biobot Analytics is a pioneering biotechnology company specializing in wastewater-based epidemiology. By analyzing sewage, Biobot transforms wastewater infrastructure into public health observatories, providing valuable insights into community health trends. Founded in 2017 by biologist Mariana Matus and architect Newsha Ghaeli, the company is headquartered in Cambridge, Massachusetts. | biobot.io | Private | Transforming wastewater into public health data | Cambridge, Massachusetts, USA | 2017 | Y Combinator, Ekistic Ventures, Refactor Capital, Liquid 2 Ventures | Active | Biobot Analytics turns wastewater into actionable public health data, detecting pathogens, illicit drugs, and other health indicators in real time. Its epidemiological reports help communities track outbreaks, assess public health measures, and identify emerging risks early. By combining molecular analysis with AI-driven insights, Biobot is transforming how health trends are monitored and managed. | Traditional public health monitoring methods often rely on clinical data, which can be delayed and may not capture asymptomatic cases. Biobot addresses this by providing real-time, community-level health insights through wastewater analysis. | By transforming wastewater into a source of public health data, Biobot enables early detection of disease outbreaks, monitoring of substance use trends, and assessment of public health interventions. | They provide the cost effective alternative monitoring solution that is not invasive and enabling proactive responses to emerging health threats. | Data as a Service Model, Subscription Model. As well as providing a consulting service for their customer | Biobot utilizes advanced molecular technologies and artificial intelligence to analyze sewage, transforming raw data into actionable public health insights. | Biobot Analytics has carved out a niche in wastewater-based epidemiology, offering a unique approach to public health monitoring by turning sewage data into actionable insights. The company has effectively leveraged its data-driven model to provide communities with early detection of outbreaks and trends, positioning itself as an essential tool for public health management. Its strong value proposition, well-timed market entry, and innovative product design have been key drivers of its success.
While Biobot’s business model is solid and its financial management has been effective, differentiation remains a challenge as other players enter the wastewater analytics space. Leadership has navigated growth well, though resilience and adaptability could be stronger in responding to industry shifts. Marketing efforts have been effective in driving adoption, but continued expansion and visibility will be crucial for maintaining its position in the market.
Biobot’s ability to meet customer needs and navigate regulatory frameworks has reinforced its credibility, and its focus on timing and innovation has kept it ahead of emerging trends. Moving forward, scaling operations and strengthening competitive advantages will be essential to sustaining growth. The company has built a strong foundation, but long-term success will depend on its ability to refine its strategy, enhance differentiation, and solidify its leadership in the industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/sawasdeeponnoah_5794019_91318768_Biobot Analytics-1.docx | Healthcare Profile | null | N/A (Private Company) | N/A | Raised $2.5 million in seed funding in 2018 | N/A | : N/A | 3 | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 5 | 5 |
Clipboard Health is a fast-growing healthcare technology company that connects healthcare professionals with job opportunities at healthcare facilities. The platform simplifies the hiring process by enabling healthcare providers to quickly find qualified professionals for open shifts. By leveraging technology, Clipboard Health aims to make the workforce management process more efficient, cost effective, and user friendly for both employers and employees. The company’s mission is to improve the healthcare industry by addressing staffing challenges, promoting better work life balance for healthcare professionals, and providing quality care for patients. With a focus on innovation, Clipboard Health aims to streamline the staffing process and offer a platform that fosters connections, improves communication, and promotes growth within the healthcare workforce. Ultimately, the company is driven by its vision of transforming healthcare staffing through technology. | https://www.clipboardhealth.com/about | Private | We seek to revolutionize the market for healthcare talent by paving the way in reliability, affordability, and ease of use for both facilities and healthcare professionals. | San Franscisco, CA | 2016 | 13 investors - Y combinator and initialized capital | focused on growth and expansion by connecting healthcare professionals with open shifts at healthcare facilities, offering a tech driven platform that makes staffing reliable | Clipboard Health offers a platform that connects healthcare professionals with open shifts at healthcare facilities, providing a seamless process for both works and employers. Their service includes job matching for various healthcare positions – nurses, aides, and other support staff – allowing professionals to select shifts that fit their schedule. The platform ensures that healthcare facilities can fill staffing gaps quickly with qualified individuals to improve operational efficiency and reduce labor cost. | Healthcare facilities often struggle to find qualified staff for open shifts which leads to staff shortages and increased operational strain | Provides a tech driven platform that connects healthcare professionals to flexible job opportunities | Providing efficient staffing solutions for all healthcare facilities. | Advertising, Fixed Price, Subscription, VAD/VAR, Channel, Subscription. Include metrics. | 1 paragraph to describe tech being leveraged, summary of tech stack. | Clipboard Health has emerged as a successful business in the healthcare staffing world by addressing the immediate need for flexible, digital solutions that connect healthcare professionals with employers. The company offers a platform that allows nurses to choose shifts based on their availability which streamlines the process for both healthcare workers and facilities. By capitalizing on the trends in the economy and the demand for flexible work, Clipboard Health has positioned itself as a key player in an industry traditionally characterized by difficult and inefficient staffing practices. The company’s success is largely due to its strong market fit and value proposition. It meets the needs of healthcare professionals seeking better work-life balance while offering healthcare providers an efficient way to fill staffing gaps. Despite challenges with pay and service stability, Clipboard Health has built a loyal user base, with its leadership team and innovative business model driving significant growth. The company has also benefited from the timing of its entry into the market, aligning with the increasing demand for temporary healthcare staffing and digital workforce solutions. With continued adaptation to customer concerns, Clipboard Health has the ability to maintain its success and grow more in the competitive healthcare staffing landscape. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/shahpiya_5664667_91331767_Spring2025_BusinessProfileFormat_Healthcare.docx | Healthcare Profile | Current valuation is $1.3B and revenue is $279.1M per year | N/A | N/A | $94.1 million from series C and more | null | N/A | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 4 |
Cala Health is a bioelectronic medicine company dedicated to transforming the standard of care for chronic diseases through innovative, non-invasive therapies. Founded in 2014 and headquartered in the San Francisco Bay Area, Cala Health combines advancements in neuroscience and technology to develop wearable neuromodulation devices that provide individualized peripheral nerve stimulation.
The company's mission is to improve the lives of patients suffering from chronic diseases by developing cutting-edge, non-invasive solutions that address the root causes of various health conditions. By combining deep scientific research with advanced technology, Cala Health strives to create a lasting impact on healthcare and empower patients to take control of their well-being. With a commitment to pioneering technology, Cala Health aims to expand its innovative therapies across various medical fields, including neurology, cardiology, and psychiatry, to help individuals in their struggle with chronic diseases.
Cala Health's flagship product, the Cala kIQ™ System, is the first non-invasive, wrist-worn prescription therapy designed to aid in the temporary relief of hand tremors in adults with essential tremor and Parkinson's disease. This FDA-cleared device delivers Transcutaneous Afferent Patterned Stimulation (TAPS) therapy, offering patients a clinically validated alternative to traditional treatments. | https://calahealth.com | private | "Wearable Medicine for People with Chronic Conditions." | San Mateo California | 2016 | Canaan Partners, Bessemer Venture Partners, Section 32, Sands Capital Ventures | Growth | Cala Health offers bioelectronic treatments through its wearable medical devices designed to manage chronic conditions, particularly focusing on essential tremor. Their flagship product, the **Cala Trio**, is a prescription device that uses neuromodulation technology to reduce hand tremors in patients. The company also provides **Cala Connect**, a software platform that enables patients and healthcare providers to track and manage treatment progress. In addition to these products, Cala Health is exploring other bioelectronic medicine solutions to treat various neurological and chronic conditions using non-invasive, drug-free technology.1-2. | Cala Health addresses the challenge of managing chronic conditions like essential tremor by providing non-invasive, drug-free solutions to reduce symptoms such as hand tremors. | Their wearable devices offer an alternative to traditional treatments, improving quality of life for patients with minimal side effects. | Cala Health’s value proposition lies in providing patients with chronic conditions, like essential tremor, a non-invasive, drug-free treatment option that significantly reduces symptoms, improving daily functioning and quality of life. Their wearable devices offer a convenient, personalized solution that empowers patients to manage their condition without the need for surgery or reliance on medications. | Fixed Price | Cala Health uses **neuromodulation technology** in its wearable devices, like the Cala Trio, to reduce essential tremor symptoms through electrical stimulation. The devices integrate with **Cala Connect**, a cloud-based platform that tracks patient progress and provides insights for healthcare providers. The tech stack combines wearable hardware, biosignal processing, and data analytics to deliver personalized, non-invasive treatment. | Cala Health has been successful due to its innovative approach to addressing chronic conditions like essential tremor with non-invasive, drug-free wearable devices. The company recognized the need for alternatives to traditional treatments such as medication and surgery, offering patients a more convenient and safer solution through its neuromodulation technology. By providing an easy-to-use wearable device, the Cala Trio, along with a data-driven platform for patient monitoring, Cala Health has been able to meet a significant market demand in the healthcare sector.
Cala Health’s success can also be attributed to its strong leadership, particularly from co-founder and CEO Dr. Kate Rosenbluth, who has a background in both healthcare and technology. The company has built a culture of innovation and patient-centric care, ensuring that its products are not only effective but also accessible. The strategic partnerships with investors have enabled Cala Health to secure the funding necessary for product development, clinical trials, and market expansion, while its ability to navigate the complex regulatory landscape has allowed for widespread adoption of its products.
Additionally, Cala Health has differentiated itself from competitors by focusing specifically on wearable bioelectronics, which is a growing niche in the medical device market. With a solid value proposition and clear focus on improving patients' quality of life, the company continues to expand its reach. The success of Cala Health demonstrates how combining cutting-edge technology with a patient-focused approach can lead to tangible results in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/solorzanomariaisabella_5611636_91315321_Spring2025_CalaHealth.docx | Healthcare Profile | $15 million annually | null | n/a | Series B: In 2021, Cala Health raised $77 million to support the development and commercialization of its bioelectronic devices. Series A: Prior to that, Cala Health secured $22 million in a Series A round to advance its wearable medical technology. | n/a | n/a | 5 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Abridge is a medical AI company founded in 2018, headquartered in Pittsburgh, Pennsylvania. Its mission is to deepen understanding of healthcare by transforming doctor-patient conversations into real-time, structured clinical records. Abridge uses enterprise level generated artificial intelligence and deep electronic medical record integration to help clinical doctors record more effectively and focus on patient care. The platform was built with transparency and trust in mind, and set high standards for responsible artificial intelligence in medicine. | https://www.abridge.com | Private | null | Pittsburgh, Pennsylvania, United States | 2018 | IVP, Elad Gil | Growth | Abridge provides AI tools that convert real-time conversations between doctors and patients into structured notes, and integrate them with electronic medical record systems to improve document efficiency and reduce the burden on doctors. The service includes recording, transcription, summarization, and review, suitable for medical institutions and individual practitioners. | Clinical documentation is time-consuming and takes doctors' attention away from patients. | Abridge uses AI to turn medical conversations into structured notes in real time. | It helps doctors save time and focus more on patients, improving both care and workflow. | Abridge adopts a subscription based model to provide AI based document tools for healthcare providers. Hospitals and clinics pay to access the platform, which helps improve efficiency and reduce clinical fatigue. | Abridge utilizes natural language processing (NLP) and machine learning to convert real-time doctor-patient conversations into structured clinical records. It integrates with major electronic health record (EHR) systems and uses secure cloud based infrastructure to ensure data privacy and compliance with healthcare regulations. | Abridge has become an outstanding medical AI startup by completely changing the way clinical conversations are recorded. Its AI driven platform converts real-time doctor-patient conversations into structured notes, which helps reduce administrative burden and improve efficiency. With strong growth, solid funding, and high recognition in KLAS rankings, Abridge has demonstrated the value of focusing on healthcare innovation. Its success lies in combining generative artificial intelligence with deep EMR integration, directly addressing the main pain points of clinical doctors, thereby providing better care and saving time. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/tanzunyu_5671125_91338223_Spring2025_BusinessProfileFormat (Healthcare).docx | Healthcare Profile | Not publicly disclosed | N/A | N/A | $57.5M total funding over 4 rounds | null | N/A | 5 | -1 | 5 | 5 | 4 | 5 | 4 | 5 | 5 | 5 | 5 | 5 |
Garner’s mission is to allow people to get access to high-quality and affordable healthcare. Garner attempts to use data-driven insights and financial incentives to ensure patients get the best care possible and stay healthy. Moreover, Garner hopes to promote high-quality healthcare and willingness to improve by rewarding top healthcare organizations by connecting them to more patients. | getgarner.com | Private | null | New York City, NY | 2019 | Redpoint, Founders Found, Thrive Capital, Optum Ventures, Maverick Ventures, CoFound Partners, BoxGroup | Growth | Garner helps companies’ employees to find the best doctors and healthcare within their network. Garner also helps employees save money on copays when visiting top doctors. Garner DataPro offers data-driven insights to other healthcare organizations so that they can improve their services and also get referred Garner users based on how well they do. | Finding the correct healthcare is often confusing and not transparent. Furthermore, copays and deductibles tend to catch people off guard. Finally, healthcare organizations struggle with efficiency and patient satisfaction. | Garner offers a platform that clearly lays out healthcare options, highlighting the best ones. Garner covers costs when going with certain top organizations. Garner also offers data insights for healthcare organizations to improve themselves. | Using Garner’s platform, employer’s will benefit from healthier, happier and more productive employees. Employees can find the best healthcare at low costs. Healthcare organizations are able to obtain advice and insights from a platform that deals with potential patients. | Garner has a B2B business model. Employers pay so their employees can have access to this platform. Healthcare organizations pay to get access to Garner’s support and data-driven insights. | Garner uses data science and machine learning to offer data-driven insights to healthcare organizations while also using it to suggest the best healthcare to patients. Garner uses cloud technology through AWS and Snowflake. | Garner health was and continues to be successful because of its approach to simplifying healthcare. Today, healthcare options tend to be too complex or not transparent, so a patient can never understand how to get the best care they need. Garner successfully solves this problem by connecting patients to the right organizations so that they can get the best care with little to no cost. Moreover, Garner’s ability to provide data-driven insights to healthcare organizations is extremely valuable to those organizations. These organizations will know how to better tailor their services to potential patients. Garner Health is also popular among employers as it has been proven to reduce the average number of sick days taken by employees. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/tatikondanithin_5568199_91323342_Garner Health Profile.docx | Healthcare Profile | null | null | null | $70M total, 4 rounds | null | null | 3 | 3 | 2 | 4 | 1 | 3 | 2 | 4 | 5 | 4 | 3 | 3 |
The mission of the company is to bring life-saving technology to everyone, regardless of their race, ethnicity, gender, religion or location. They believe that everyone deserves and should have equal access to medical care. They provide flexibility for its customers in that they can test at their own convenience at home, or wherever they want to do the test. | https://healthy.io/ | Private | Healthcare at the speed of life | Tel Aviv, Israel | 2013 | Hypergrowth | Healthy.io offers AI-powered diagnostics, including Minuteful Kidney for at home chronic kidney disease testing, Minuteful UTI for rapid UTI diagnosis, and AI-driven Wound Care for remote monitoring. The products are sold via healthcare providers, insurers, and pharmacies. | Healthy.io eliminates barriers to lab testing by enabling at-home, AI-powered diagnostics for chronic kidney disease, UTIs, and wound care. Traditional testing requires clinics, long wait times, and high costs, leading to delayed diagnoses and untreated conditions. By transforming smartphones into medical-grade tools, Healthy.io makes testing faster, more accessible, and cost-effective, improving early detection and patient outcomes. | Healthy.io's solution leverages AI and computer vision to transform smartphone cameras into clinical-grade diagnostic tools. This platform enables patients to perform tests at home—by capturing images of test strips for conditions like chronic kidney disease, UTIs, and wound care—and provides instant, accurate analysis of chemical changes. This approach eliminates the need for traditional lab visits, reducing costs and delays while improving early detection and overall patient outcomes. | Their value proposition lies in transforming smartphone cameras into clinical-grade medical devices, enabling at-home diagnostics for conditions like chronic kidney disease and wound care. By leveraging AI and machine learning, they provide lab-accurate results remotely, improving access to healthcare, early disease detection, and patient convenience, while reducing healthcare costs and gaps in care. | Healthy.io primarily operates under a Channel Business Model with elements of a VAD/VAR model. They partner with healthcare providers, pharmacies, insurance companies, and health systems to distribute its products rather than selling directly to consumers themselves. It also integrates fixed pricing for its B2B clients and subscription-based models in certain partnerships. | Healthy.io leverages AI-driven image processing, machine learning, and computer vision to turn smartphone cameras into clinical-grade diagnostic tools. Built on cloud infrastructure its platform ensures EHR compatibility, HIPAA/GDPR compliance, and real-time health insights for seamless patient-provider interactions. | Healthy.io’s success can be attributed to its unique value proposition, timing in the market, and strong leadership. By transforming smartphone cameras into clinical-grade medical devices, the company has effectively solved a major pain point in healthcare: the need for accessible, accurate, and remote diagnostics. Its FDA-cleared AI-powered urinalysis and wound care solutions provide lab-quality results from home, reducing barriers to early disease detection and treatment. This innovation aligns perfectly with growing trends in telehealth and digital health, allowing the company to stand out in a crowded market.
Unlike many startups that struggle with healthcare compliance, Healthy.io prioritized regulatory approvals (FDA, CE) early on, earning credibility among healthcare providers, insurers, and governments. Their B2B partnerships with health systems and pharmacies helped scale adoption faster than a direct-to-consumer (DTC) approach alone. Additionally, the company has demonstrated resilience by expanding from urinalysis to AI-driven wound care, proving its ability to pivot and scale based on market needs.
Lastly, strong leadership and financial backing played a critical role. Founded by Yonatan Adiri, a well-known innovator in digital health, Healthy.io has secured over $190M in funding, allowing it to continuously improve its AI models, expand globally, and establish long-term sustainability. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/throneholstsina_5794404_91298730_Healthy-1.io.docx | Healthcare Profile | $189.97M | N/A | N/A | $50M | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
|
Neko Health is a Swedish health-tech startup co-founded by Spotify’s founder Daniel Ek and entrepreneur Hjalmar Nilsonne, specializing in preventive healthcare through AI-assisted full-body scanning technology. Using 70 sensors to collect over 50 million data points in a 10-minute session, the company’s non-invasive scans analyze skin health, cardiovascular function, and metabolic indicators. With clinics in Stockholm and London, Neko Health has performed over 10,000 scans. | https://www.nekohealth.com/se/en | private | Shifting healthcare from reactive treatment to proactive prevention | Stockholm, Sweden | 2018 | Lakestar, General Catalyst, Atomico, Lightspeed | Growth | Neko’s primary offering is the Neko Body Scan, which utilizes 70+ sensors and AI analysis to detect potential health issues early, analyzing, e.g., skin anomalies. The scan takes about 10 minutes, with real-time results provided during a doctor consultation. Neko Health also offers personalized health insights, enabling users to track changes over time via a digital platform. | The late detection of serious health conditions due to a reactive healthcare system that focuses on treatment rather than early prevention. | AI-powered, non-harmful full-body scans that enable early detection of health risks, shifting healthcare from reactive treatment to proactive prevention. | Helping people to stay ahead of health risks before they become serious. It’s all about shifting from reactive treatment to proactive prevention so that customers can take control of their health. | Neko Health operates on a fixed-price, direct-to-consumer (DTC) business model, where customers pay a one-time fee per full-body scan. Each scan costs approximately €250-€300 and includes an AI-driven health analysis with a doctor consultation. | Neko’s full-body scan system uses 70+ advanced sensors to capture detailed health data. AI-driven algorithms then analyze millions of data points in real time, identifying potential health risks with greater accuracy and efficiency than traditional check-ups. This data is instantly processed and visualized for both patients and doctors, allowing for immediate insights and personalized health recommendations. By combining machine learning, computer vision, and real-time analytics, Neko Health is making preventive healthcare more accessible, data-driven, and proactive. | Neko Health is a success because it makes preventive healthcare fast, affordable, and accessible. Its AI-powered full-body scans provide real-time health insights in just 10 minutes, empowering people to detect risks early instead of waiting for symptoms. With 100,000+ on its waitlist and $260M in funding, demand proves the need for scalable, proactive health solution. Unlike costly, time-consuming MRI scans, Neko’s efficient AI-driven approach bridges the gap between innovation and everyday healthcare, making early detection mainstream. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/wimmersimon_5793578_91292754_Healthcare Business Profile_Simon Wimmer.docx | Healthcare Profile | 2024: €2.1m
2023: €500k | n.a. | n.a. | Series B: €250m
Series A: €60m | n.a. (but most likely negative) | n.a. | 5 | 3 | 4 | 2 | 4 | 5 | 4 | 5 | 3 | 4 | 5 | 5 |
Navina is a healthcare AI startup founded in 2018 that specializes in AI-driven clinical decision support. Its platform integrates seamlessly with electronic health records to help physicians process patient data more efficiently. The company’s mission is to empower healthcare providers with AI-powered insights to improve patient outcomes, reduce administrative burden, and enhance decision-making. By leveraging artificial intelligence, Navina bridges gaps in healthcare data interpretation and provides accurate, timely, and actionnable recommandations. | https://www.navina.ai/ | Private | "AI that thinks like a doctor." | New York | 2018 | ALIVE Israel HealthTech Fund, Grove Ventures, Vertex Ventures Israel, Schusterman Family Investments | Growth | Navina provides an AI-powered clinical decision support system designed to work with EHRs. The platform analyzes patient data, highlights potential diagnoses, identifies risk factors, and flags medication conflicts. By simplifying complex data, Navina helps doctors make faster, more accurate decisions, improving both efficiency and patient care. | Doctors spend too much time sifting through fragmented patient records, increasing the risk of errors and inefficiencies. | Navina’s AI consolidates and organizes patient data, presenting key insights in an easy-to-digest format for physicians. | Navina saves doctors time, reduces burnout, and improves patient care by making clinical data more accessible and actionable. | Navina operates on a subscription-based model, charging healthcare providers for access to its AI-powered platform. The company partners with hospitals, clinics, and insurers to integrate its technology into their existing workflows. | Navina uses machine learning and natural language processing to extract insights from structured and unstructured medical data. The platform integrates with major EHR systems and applies AI-driven risk stratification, predictive analytics, and clinical decision support to enhance patient care. | Navina has emerged as a leader in AI-driven clinical decision support by tackling one of healthcare’s biggest challenges: physician burnout from overwhelming administrative work. By streamlining the way doctors interact with patient data, Navina enhances efficiency and improves diagnostic accuracy.
With a strong leadership team, significant investment backing, and growing industry adoption, Navina is well-positioned for continued success. Its AI-driven approach not only reduces time spent on paperwork but also enhances patient outcomes by providing clearer insights.
As AI continues to transform healthcare, Navina stands out as a company that bridges the gap between data and decision-making, ensuring better care for patients and less stress for doctors. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/wusamantha_LATE_5659854_91343834_Spring2025_BusinessProfileFormat - Healthcare-1.docx | Healthcare Profile | null | N/A (Private company) | N/A | $100M total; latest round: $55M Series C led by Goldman Sachs | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
Pfizer Inc. is a global healthcare company that develops and sells medicines and vaccines to help people stay healthy. Based in New York City and founded in 1849, Pfizer serves patients in the United States and around the world. The company offers treatments for a wide range of health conditions, including heart issues, migraines, infections, and chronic illnesses. Some of its well-known products include Eliquis for heart health, Nurtec ODT and Zavzpret for migraines, and vaccines like Prevnar and Abrysvo to help prevent infections. Pfizer also played a major role in the fight against COVID-19, developing the Comirnaty vaccine and Paxlovid treatment.
In addition, the company provides medicines for conditions related to the immune system, rare diseases, hormone imbalances, and cancer. Its cancer treatments include widely used drugs like Ibrance and Xtandi. Pfizer also supplies medicines to hospitals and clinics, including antibiotics and injectable drugs, and helps other companies manufacture their products. The company works closely with partners like Bristol-Myers Squibb, Astellas Pharma, Merck, and BioNTech, and serves customers such as hospitals, pharmacies, healthcare providers, and government agencies. | https://www.pfizer.com/ | Public | Breakthroughs that change patients' lives | NY, New York | 1849 | null | Public | At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. They strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Pfizer’s global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.
Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on them. | Pfizer aims to solve the global need for effective, accessible treatments and vaccines for serious and widespread health conditions. | innovative, science-based medicines and vaccines that prevent illness, treat disease, and improve health outcomes worldwide. | Pfizer delivers innovative, science-driven medicines and vaccines that improve lives by addressing some of the world’s most pressing health challenges, combining cutting-edge research with global scale to make high-quality healthcare accessible to millions. | null | Pfizer leverages cutting-edge digital technologies—including AI, machine learning, real-time data modeling, remote monitoring, IoT sensors, and augmented reality—to accelerate drug development, scale global manufacturing, and ensure safe, efficient distribution of its medicines and vaccines.
During the COVID-19 pandemic, these tools enabled Pfizer to rapidly develop and distribute over 3 billion vaccine doses worldwide, making it one of the most significant digital transformations in modern healthcare. | Pfizer Inc. is a leading global biopharmaceutical company committed to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve lives. Headquartered in New York City and founded in 1849, Pfizer operates in over 125 countries and serves patients worldwide across a broad range of therapeutic areas including infectious diseases, oncology, immunology, cardiology, and rare diseases.
The company played a pivotal role in the global response to the COVID-19 pandemic through its partnership with BioNTech, developing Comirnaty, the first FDA-approved mRNA COVID-19 vaccine, and Paxlovid, an antiviral treatment. Pfizer’s digital transformation—driven by investments in AI, machine learning, and advanced manufacturing—has accelerated its ability to bring products to market efficiently and at scale.
With a robust product pipeline, strategic global partnerships, and a strong focus on science and innovation, Pfizer continues to address some of the world’s most pressing health challenges, while advancing its mission to deliver breakthroughs that change patients’ lives. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/xuchristine_LATE_5617342_91342481_Pfizer Inc.docx | Healthcare Profile | $63.6 billion | 148.14 billion | PFE (NYSE) – 31.54 (high), 24.48 (low) | null | 15.9% | 8.85 | 3 | 4 | 3 | -1 | 4 | 3 | 5 | 4 | 4 | 4 | 4 | 3 |
Atomwise strives to transform drug discovery and create better medicines using AI engines. This is achieved through the finding of small molecule drugs using a machine learning engine that combines neural networks and chemical libraries. | atomwise.com | Private | Better medicines faster | San Francisco, CA | 2012 | Y Combinators, B Capital, Khosla Ventures, Bill & Melinda Gates Foundation, Draper Associates | Growth + Turning Point with new CEO | Offers AtomNet, an AI driven platform to help users analyze molecular compounds and drug reaction and effectiveness. Atomwise also offers a screening service for clients to screen through chemical libraries to search for target compounds. Alternatively, their AI model is licensed for other organizations to adapt and introduce the model into their own drug discovery workflow. | Faster and more cost-efficient process of drug discovery | Machine learning AI model to predict molecular interaction between drugs and target proteins as well as screening through vast chemical libraries | The cost efficacy, accuracy rates, and faster speed of discovering drug compounds. | Mainly Business-To-Business model through partnerships, services, and licensing their AI technology to mainly biotech companies, pharmaceutical firms, and academic researchers. | Through their platform AtomNet, Atomwise uses neural networks to predict molecular binding to target proteins. This is done by processing through huge amounts of molecular data and chemical libraries to search and optimize for drug discovery. | Atomwise’s dual focus on technological innovation and strategic partnership has been the key to its success in carving its own space in the healthcare sector. Their ability to virtual screen enabled by their deep learning AI model analyzing molecular interactions between chemical compounds and target proteins is a unique approach to a problem: the slow speed and low efficacy of traditional methods in discovering drugs. Aside from their cutting edge technological methods, their business model that seeks business-scale partnerships in the use of their technology is only possible through their scalable AI model. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/yidabin_5202061_91337930_Atomwise Business Profile.docx | Healthcare Profile | null | null | null | $45M | null | null | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 3 | 4 |
Subsets and Splits